Mary Caffrey

Groups seeking grants under the new program must show how they can train small practices without charging the doctors or their practices.

Using an algorithm to recommend insulin dosing, both in and out of the hospital, was shown to improve glycemic control and aid population health management.

The partnership will allow Medtronic to scale Canary Health's diabetes prevention programs to reach a wider audience and bring Canary's self-management platform into customer support for its devices.

An executive summary of the report on the PAN Foundation roundtable, presented with The American Journal of Managed Care, discussed the shift from the problem of the "uninsured" to the "underinsured."

The diabetes advocacy community has long sought Medicare coverage for continuous glucose monitoring (CGM) systems, but the technology has been deemed "precautionary." Abstracts presented at last week's ADA Scientific Sessions could help build a case for updating FDA's clearance to use CGM for dosing, removing a hurdle to Medicare coverage.

Reseachers are studying whether drugs that have been approved for treating type 2 diabetes can be used in combination with insulin to avoid both variablity in blood glucose and weight gain.

A packed session greeted the highly anticipated results of the LEADER trial, which found that the GLP-1 receptor agonist liraglutide has cardiovascular benefits in high-risk patients with diabetes.

Data from CDC consistently show that low-income, minority groups are at higher risk for diabetes, for genetic but especially for environmental reasons.

Evidence presented Sunday at the 76th Scientific Sessions of the American Diabetes Association comes as competition is heating up over a pair of therapies that combine insulin with a GLP-1 receptor agonist.

Intarcia Therapeutics anticipates filing for FDA approval at the end of the third quarter of 2016. At this year's ADA presentation, Julio Rosenstock, MD, said the insertion method for the novel therapy delivery device continues to improve.

In an ADA session called "Follow the Money," panelists led by Joslin Diabetes Center's Robert A. Gabbay, MD, PhD, FACP, discussed the diabetes cost burden, insulin costs, and payment models.

A poster at an ADA session on barriers and facilitators to novel care found that top concerns of patients with diabetes often have nothing to do with the disease. Other studies looked at which comorbidities contribute the most to readmissions or length of stay, and how an intervention that focused on transitions of care reduced A1C in patients with uncontrolled diabetes.

Robert M. Anderson, EdD, of the University of Michigan, has spent his career spreading a message that patients respond best when education programs address what they want, not what an expert thinks they need.

A commentary in the special issue of JAMA on obesity argues that the nation has reached a point where therapy can no longer undo the damage of poor diets and lack of exercise, and a reckoning of policy change is needed.

The appellate ruling flatly rejected the request to overturn regulators' approval of Horizon's tiered network. But this is not the end of litigation over the controversial plan.

Older patients and those with other complications are at greatest risk.

After reading two CDC accounts of this strange set of symptoms among gay men, Anthony S. Fauci, MD, recalls redirecting his research efforts to combat a disease that didn't even have a name.

The first study sheds light on the complex interaction between underlying metabolic risk and breast cancer.

Cardiovascular outcomes trials, new technologies, and the fight over what we eat will be featured at the upcoming 76th Scientific Sessions of the American Diabetes Association in New Orleans.

Donald B. Verrilli won key cases to keep intact the Affordable Care Act. With his winning argument in the 2015 case to extend marriage equality to all states, same-sex couples could no longer be denied the right to cover a spouse on an insurance policy or be named next-of-kin for medical decisions.

The 57-year-old music icon officially became the most high-profile victim of the nation's opioid epidemic.

The study highlights results from the population largely denied CGM coverage under Medicare.

The acquisition lets Myriad acquire the maker of EndoPredict, which just received reimbursement status from Aetna and meets ASCO guidelines for payment by Medicare contractors.

The proposal calls for 2-year and 10-year goals to gradually reduce Americans' salt intake. This strategy has been used in the past when it became clear that FDA would seek ways to limit sugar consumption.

Not everyone agrees that payers should risk losing these healthier consumers for the long haul.

Guidelines and an article in the issue take on the thorny question of how obese type 2 patients must be for surgery to be effective in improving glycemic control.

Part 1: See Part 2 in the September issue of Evidence-Based Diabetes Management.

Training seniors to manage their own diabetes takes many hands--most notably, those of the patients themselves. A look at how a diabetes management program serving a diverse population approaches this task.

The collaboration is the latest in a series of partnerships for diabetes care announced by the medical device maker.

Data sharing in precision medicine has not been without controversy. Some genetic testing companies say security on public databases is less than stellar, giving them a reason to decline sharing their information warehouses.